|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Retrospective Clinical Study |
Departments of Neurosurgery (R.J.J., D.A.-S., F.F.L, Z.L.G., W.M.S., D.M.W., R.S.) and Pathology (G.N.F.), The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030
3 Address correspondence and reprint requests to Raymond Sawaya, Department of Neurosurgery, Box 442, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
Abstract
Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. At The University of Texas M. D. Anderson Cancer Center, we retrospectively reviewed a consecutive series of 81 patients whose imaging studies suggested glioma and who underwent stereotactic biopsy followed by craniotomy/resection (within 60 days) between 1993 and 1998. All relevant clinical and imaging information was reviewed, including computerized volumetric analysis of the tumors based on pre- and postoperative MRI. Stereotactic biopsy was performed at institutions other than M. D. Anderson in 78 (96%) of 81 patients. The majority of tumors were located either in eloquent brain (36 of 81 = 44%) or near-eloquent brain (41 of 81 = 51%), and this frequently was the rationale cited for performing stereotactic biopsy. Gross total resection (>95%) was achieved in 46 (57%) of 81 patients, with a median extent of resection of 96% for this series. Diagnoses based on biopsy or resection in the same patient differed in 40 (49%) of 82 cases. This discrepancy was reduced to 30 (38%) of 80 cases when the biopsy slides were reviewed preoperatively by each of three neuropathologists at M. D. Anderson. Major neurologic complications occurred in 10 (12.3%) of 81 surgical patients and 3 (3.7%) of 81 patients undergoing biopsy. Surgical morbidity was probably higher in our series than it would be for glioma patients in general because our patients represent a highly selected subset of glioma patients whose tumors present a technical challenge to remove. Stereotactic biopsy is frequently inaccurate in providing a correct diagnosis and is associated with additional risk and cost. If stereotactic biopsy is performed, expert neuropathology consultation should be sought.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Bisdas, M. Kirkpatrick, P. Giglio, C. Welsh, M.V. Spampinato, and Z. Rumboldt Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease? AJNR Am. J. Neuroradiol., April 1, 2009; 30(4): 681 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hirai, R. Murakami, H. Nakamura, M. Kitajima, H. Fukuoka, A. Sasao, M. Akter, Y. Hayashida, R. Toya, N. Oya, et al. Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study AJNR Am. J. Neuroradiol., September 1, 2008; 29(8): 1505 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Law, R. J. Young, J. S. Babb, N. Peccerelli, S. Chheang, M. L. Gruber, D. C. Miller, J. G. Golfinos, D. Zagzag, and G. Johnson Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Radiology, May 1, 2008; 247(2): 490 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lu, E. Pollack, R. Young, J.S. Babb, G. Johnson, D. Zagzag, R. Carson, J.H. Jensen, J.A. Helpern, and M. Law Predicting Grade of Cerebral Glioma Using Vascular-Space Occupancy MR Imaging AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 373 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.K. Ellika, R. Jain, S.C. Patel, L. Scarpace, L.R. Schultz, J.P. Rock, and T. Mikkelsen Role of Perfusion CT in Glioma Grading and Comparison with Conventional MR Imaging Features AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1981 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Law, R. Young, J. Babb, M. Rad, T. Sasaki, D. Zagzag, and G. Johnson Comparing Perfusion Metrics Obtained from a Single Compartment Versus Pharmacokinetic Modeling Methods Using Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging with Glioma Grade. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1975 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Law, S. Oh, J. S. Babb, E. Wang, M. Inglese, D. Zagzag, E. A. Knopp, and G. Johnson Low-Grade Gliomas: Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging--Prediction of Patient Clinical Response Radiology, February 1, 2006; 238(2): 658 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Pope, J. Sayre, A. Perlina, J. P. Villablanca, P. S. Mischel, and T. F. Cloughesy MR Imaging Correlates of Survival in Patients with High-Grade Gliomas AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2466 - 2474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. M. Maia Jr, S. M. F. Malheiros, A. J. da Rocha, C. J. da Silva, A. A. Gabbai, F. A. P. Ferraz, and J. N. Stavale MR Cerebral Blood Volume Maps Correlated with Vascular Endothelial Growth Factor Expression and Tumor Grade in Nonenhancing Gliomas AJNR Am. J. Neuroradiol., April 1, 2005; 26(4): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Evans, K. D. Judy, I. Dunphy, W. T. Jenkins, W.-T. Hwang, P. T. Nelson, R. A. Lustig, K. Jenkins, D. P. Magarelli, S. M. Hahn, et al. Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors Clin. Cancer Res., December 15, 2004; 10(24): 8177 - 8184. [Abstract] [Full Text] [PDF]
|
|
|
|
